9 Persistent Myths About HRT and Cancer Risk That the Evidence Contradicts
The number of women who've told me they suffered through years of broken sleep, crushing anxiety, and joint pain because their doctor said 'HRT causes cancer' — and left it at that — is heartbreaking. The fear was real, but it was built on a foundation that the science has since substantially dismantled. Every woman deserves to make this decision with accurate information, not a 20-year-old scare story.
Learn more about Rose →Myth: The WHI study proved HRT causes breast cancer
The Women's Health Initiative trial that sparked the global HRT panic used a single oral combined HRT formulation — conjugated equine estrogen plus medroxyprogesterone acetate — in women with an average age of 63, many of whom had not used hormones for over a decade. The absolute increased risk of breast cancer in the combined arm was approximately 8 extra cases per 10,000 women per year — a relative risk that was statistically borderline and smaller than the risk associated with drinking one glass of wine daily. Crucially, the estrogen-only arm of the same study showed a statistically significant reduction in breast cancer risk, a finding that received almost no media coverage.
Myth: All HRT carries the same cancer risk
HRT is not a single drug — it's a category covering dozens of formulations, delivery routes, and hormone types, each with a distinct risk profile. Current evidence suggests that transdermal estrogen (patches, gels, sprays) does not carry the elevated blood clot risk of oral estrogen and appears to have a more favourable safety profile overall. The type of progestogen matters enormously too: micronised progesterone (body-identical) appears to carry a lower breast cancer signal than synthetic progestogens like medroxyprogesterone acetate, based on the large French E3N cohort study.
Myth: HRT risk is the same whether you start at 50 or 70
Timing of HRT initiation relative to menopause significantly affects the benefit-risk calculation — a concept now called the 'timing hypothesis' or 'window of opportunity.' Evidence from multiple analyses, including reanalysis of WHI data, suggests that women who begin HRT within ten years of menopause or before age 60 show a markedly better cardiovascular and overall mortality profile than those who start much later. Starting HRT at 70 in a woman who has been estrogen-deficient for two decades is a physiologically different intervention to starting it at 50 in a woman whose symptoms are acute and whose arteries are still healthy.
Myth: Breast cancer risk from HRT is uniquely dangerous compared to other lifestyle factors
Putting the breast cancer signal from combined HRT into genuine context is something the original 2002 coverage almost entirely failed to do. The increase in breast cancer risk associated with combined HRT is comparable to — and in many analyses smaller than — the risk conferred by obesity, alcohol consumption, or physical inactivity, none of which generate the same level of medical alarm. A woman with a BMI over 30 has a higher relative breast cancer risk than a lean woman on body-identical HRT, yet no clinician tells her to avoid weight gain the way they warn her off hormones.
Myth: HRT increases ovarian cancer risk significantly
A 2015 meta-analysis in The Lancet did find a modest association between HRT use and ovarian cancer, but the absolute numbers tell a more measured story: roughly one extra case per 1,000 HRT users over five years of use. Ovarian cancer is relatively rare, and the absolute risk increase is small enough that most clinical guidelines, including those from the British Menopause Society, consider it a factor to discuss rather than a reason to withhold treatment. The risk also appears to diminish after HRT is stopped.
Myth: HRT increases endometrial (womb) cancer risk
Unopposed estrogen — estrogen given without progestogen to women who still have a uterus — does carry a well-established risk of endometrial cancer, which is exactly why combined HRT (estrogen plus progestogen) is the standard of care for women who haven't had a hysterectomy. When progestogen is added appropriately, it protects the uterine lining and the endometrial cancer risk is neutralised or even reduced below baseline. This is not a myth to fear but a physiological mechanism that's been successfully managed in clinical practice for decades.
Myth: Women with a family history of breast cancer cannot use HRT
A family history of breast cancer is a factor to weigh carefully in HRT discussions, but it is not an automatic contraindication according to current evidence or major menopause society guidelines. For women who carry a BRCA1 or BRCA2 mutation, the picture is more nuanced and requires specialist input — but even then, HRT use following risk-reducing surgery is increasingly supported. For the much larger group of women with a first-degree relative who had breast cancer, there is no high-quality evidence that HRT meaningfully compounds that inherited risk in the short-to-medium term.
Myth: HRT increases the risk of dying from breast cancer
Even in studies where HRT has been associated with a modest increase in breast cancer incidence, the same data frequently shows no increase in breast cancer mortality — and in some analyses, a reduction. One proposed explanation is that estrogen-associated breast cancers tend to be lower grade and more hormone-receptor-positive, making them more treatable. The WHI data itself showed no statistically significant increase in breast cancer mortality in the combined HRT arm, a nuance that was almost entirely absent from the coverage that followed publication.
Myth: The medical consensus is still against HRT
The clinical landscape has shifted substantially since 2002, even if public perception and some older practitioners haven't caught up. Major menopause societies — including the British Menopause Society, the Menopause Society (formerly NAMS) in North America, and the International Menopause Society — now state clearly that for healthy women under 60 or within ten years of menopause, the benefits of HRT outweigh the risks for the majority of women with significant symptoms. The 2022 NICE guideline update in the UK explicitly acknowledged that earlier guidance had overstated HRT risks and was contributing to undertreatment.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.